KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Intangibles (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Intangibles for 15 consecutive years, with $16.3 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Intangibles fell 4.85% year-over-year to $16.3 billion, compared with a TTM value of $16.3 billion through Sep 2024, down 4.85%, and an annual FY2023 reading of $16.7 billion, down 4.43% over the prior year.
  • Intangibles was $16.3 billion for Q3 2024 at Thermo Fisher Scientific, up from $15.5 billion in the prior quarter.
  • Across five years, Intangibles topped out at $20.1 billion in Q4 2021 and bottomed at $11.9 billion in Q4 2021.
  • Average Intangibles over 5 years is $15.8 billion, with a median of $16.3 billion recorded in 2024.
  • The sharpest move saw Intangibles skyrocketed 58.56% in 2021, then decreased 13.28% in 2022.
  • Year by year, Intangibles stood at $12.7 billion in 2020, then surged by 58.56% to $20.1 billion in 2021, then fell by 13.28% to $17.4 billion in 2022, then fell by 4.43% to $16.7 billion in 2023, then fell by 2.45% to $16.3 billion in 2024.
  • Business Quant data shows Intangibles for TMO at $16.3 billion in Q3 2024, $15.5 billion in Q2 2024, and $16.0 billion in Q1 2024.